Revolution Medicines begins Phase 3 RASolute 309 trial
Revolution Medicines said it has begun treating patients in its Phase 3 RASolute 309 trial evaluating RASONQUE (daraxonrasib) plus zoldonrasib as a first-line treatment for metastatic RAS G12D pancreatic cancer.